1-20 of 34
Darren K. McGuire
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58

YU MI KANG, GIORGIO E.M. MELLONI, AVIVIT CAHN, ITAMAR RAZ, FILIPE MOURA, DEEPAK L. BHATT, SILVIO E. INZUCCHI, LAWRENCE A. LEITER, DARREN K. MCGUIRE, JOHN WILDING, INGRID A. GAUSE-NILSSON, JAN OSCARSSON, NICHOLAS MARSTON, CHRISTIAN T. RUFF, MARC S. SABATINE, STEPHEN D. WIVIOTT
Journal: Diabetes
Diabetes 2024;73(Supplement_1):1896-LB
https://doi.org/10.2337/db24-1896-LB
Published: 14 June 2024
View article titled, 1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58
Meeting Abstracts

1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58

YU MI KANG, GIORGIO E.M. MELLONI, AVIVIT CAHN, ITAMAR RAZ, FILIPE MOURA, DEEPAK L. BHATT, SILVIO E. INZUCCHI, LAWRENCE A. LEITER, DARREN K. MCGUIRE, JOHN WILDING, INGRID A. GAUSE-NILSSON, JAN OSCARSSON, NICHOLAS MARSTON, CHRISTIAN T. RUFF, MARC S. SABATINE, STEPHEN D. WIVIOTT
Journal: Diabetes
Diabetes 2024;73(Supplement_1):1895-LB
https://doi.org/10.2337/db24-1895-LB
Published: 14 June 2024
View article titled, 1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58
Meeting Abstracts

481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV

JOSEPH M. KIM, DEEPAK L. BHATT, SAMUEL DAGOGO-JACK, DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, RICHARD E. PRATLEY, CHIH-CHIN LIU, NILO B. CATER, ROBERT FREDERICH, JAMES P. MANCUSO, CHRISTOPHER P. CANNON
Journal: Diabetes
Diabetes 2022;71(Supplement_1):481-P
https://doi.org/10.2337/db22-481-P
Published: 01 June 2022
View article titled, 481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV
Meeting Abstracts

865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV

SAMUEL DAGOGO-JACK, CHRISTOPHER P. CANNON, DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, JIE LIU, CHIH-CHIN LIU, ROBERT FREDERICH, JAMES P. MANCUSO, RICHARD E. PRATLEY
Journal: Diabetes
Diabetes 2022;71(Supplement_1):865-P
https://doi.org/10.2337/db22-865-P
Published: 01 June 2022
View article titled, 865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV
Meeting Abstracts

796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV

DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, BERNARD CHARBONNEL, SAMUEL DAGOGO-JACK, RICHARD E. PRATLEY, WEICHUNG J. SHIH, MARIO MALDONADO, ANNPEY PONG, IRA GANTZ, ROBERT FREDERICH, JAMES P. MANCUSO, URSZULA MASIUKIEWICZ, CHRISTOPHER P. CANNON
Journal: Diabetes
Diabetes 2021;70(Supplement_1):796-P
https://doi.org/10.2337/db21-796-P
Published: 01 June 2021
View article titled, 796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV
Meeting Abstracts

788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58

AVIVIT CAHN, STEPHEN D. WIVIOTT, OFRI MOSENZON, SABINA MURPHY, ERICA L. GOODRICH, DEEPAK L. BHATT, LAWRENCE A. LEITER, DARREN K. MCGUIRE, JOHN WILDING, INGRID A. GAUSE-NILSSON, ANNA MARIA LANGKILDE, MARC S. SABATINE, ITAMAR RAZ
Journal: Diabetes
Diabetes 2021;70(Supplement_1):788-P
https://doi.org/10.2337/db21-788-P
Published: 01 June 2021
View article titled, 788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58
Meeting Abstracts

791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV

RICHARD E. PRATLEY, SAMUEL DAGOGO-JACK, BERNARD CHARBONNEL, DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, MARGARET N. ESSEX, PHILIP L.S. JONES, JIE LIU, INGRID A. ADAMSONS, DAVID LAWRENCE, WEICHUNG J. SHIH, CHRISTOPHER P. CANNON
Journal: Diabetes
Diabetes 2021;70(Supplement_1):791-P
https://doi.org/10.2337/db21-791-P
Published: 01 June 2021
View article titled, 791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV
Meeting Abstracts

783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV

BERNARD CHARBONNEL, SAMUEL DAGOGO-JACK, CHRISTOPHER P. CANNON, DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, WEICHUNG J. SHIH, JIE LIU, ANNPEY PONG, IRA GANTZ, ROBERT FREDERICH, JAMES P. MANCUSO, RICHARD E. PRATLEY
Journal: Diabetes
Diabetes 2021;70(Supplement_1):783-P
https://doi.org/10.2337/db21-783-P
Published: 01 June 2021
View article titled, 783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV
Meeting Abstracts

785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV

SAMUEL DAGOGO-JACK, ROBERT FREDERICH, BERNARD CHARBONNEL, JIE LIU, CHRISTOPHER P. CANNON, HARRY SHI, DARREN K. MCGUIRE, DAVID CHERNEY, FRANCESCO COSENTINO, WEICHUNG J. SHIH, URSZULA MASIUKIEWICZ, IRA GANTZ, RICHARD E. PRATLEY
Journal: Diabetes
Diabetes 2021;70(Supplement_1):785-P
https://doi.org/10.2337/db21-785-P
Published: 01 June 2021
View article titled, 785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV
Meeting Abstracts

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

SAMUEL DAGOGO-JACK, RICHARD E. PRATLEY, DAVID CHERNEY, BERNARD CHARBONNEL, DARREN K. MCGUIRE, FRANCESCO COSENTINO, WEICHUNG J. SHIH, JIE LIU, ROBERT FREDERICH, JAMES P. MANCUSO, ANNASWAMY RAJI, IRA GANTZ
Journal: Diabetes
Diabetes 2021;70(Supplement_1):786-P
https://doi.org/10.2337/db21-786-P
Published: 01 June 2021
View article titled, 786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV
Journal Articles

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Katherine R. Tuttle, Frank C. Brosius, III, Matthew A. Cavender, Paola Fioretto, Kevin J. Fowler, Hiddo J.L. Heerspink, Tom Manley, Darren K. McGuire, Mark E. Molitch, Amy K. Mottl, Leigh Perreault, Sylvia E. Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner, Vlado Perkovic
Journal: Diabetes
Diabetes 2021;70(1):1–16
https://doi.org/10.2337/dbi20-0040
Published: 26 October 2020
View article titled, SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Open the PDF for SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation in another window
Meeting Abstracts

162-OR: Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial

JULIO ROSENSTOCK, NIKOLAUS MARX, DARREN K. MCGUIRE, BERNARD ZINMAN, MARK ESPELAND, JYOTHIS T. GEORGE, MICHAELA MATTHEUS, ODD ERIK JOHANSEN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):162-OR
https://doi.org/10.2337/db20-162-OR
Published: 01 June 2020
View article titled, 162-OR: Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial
Meeting Abstracts

303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial

ITAMAR RAZ, STEPHEN D. WIVIOTT, HIDDO L. HEERSPINK, JAMIE P. DWYER, AVIVIT CAHN, ERICA L. GOODRICH, SABINA MURPHY, ALIZA ROZENBERG, ILAN YANUV, JOHN WILDING, LAWRENCE A. LEITER, DEEPAK L. BHATT, DARREN K. MCGUIRE, RONALD C. MA, TSVETALINA TANKOVA, MARTIN FREDRIKSSON, INGRID A. GAUSE-NILSSON, ANNA MARIA LANGKILDE, MARC S. SABATINE, OFRI MOSENZON
Journal: Diabetes
Diabetes 2020;69(Supplement_1):303-OR
https://doi.org/10.2337/db20-303-OR
Published: 01 June 2020
View article titled, 303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial
Meeting Abstracts

403-P: Impact of Diabetes-Related Factors and Background Antihyperglycemic Therapy on the Efficacy and Safety of Ticagrelor Added to Aspirin: Insights from the THEMIS Trial

LAWRENCE A. LEITER, DEEPAK L. BHATT, DARREN K. MCGUIRE, KIM FOX, TABASSOME SIMON, SHAMIR MEHTA, ELI LEV, ROBERT G. KISS, ANTHONY J. DALBY, HECTOR BUENO, WILHELM RIDDERSTRÅLE, ANDERS HIMMELMANN, JAYNE PRATS, YUYIN LIU, JANE J. LEE, JOHN AMERENA, MIKHAIL N. KOSIBOROD, PHILIPPE G. STEG
Journal: Diabetes
Diabetes 2020;69(Supplement_1):403-P
https://doi.org/10.2337/db20-403-P
Published: 01 June 2020
View article titled, 403-P: Impact of Diabetes-Related Factors and Background Antihyperglycemic Therapy on the Efficacy and Safety of Ticagrelor Added to Aspirin: Insights from the THEMIS Trial
Meeting Abstracts

926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial

MARK ESPELAND, RICHARD E. PRATLEY, JULIO ROSENSTOCK, TAKASHI KADOWAKI, YUTAKA SEINO, BERNARD ZINMAN, NIKOLAUS MARX, DARREN K. MCGUIRE, KNUT R. ANDERSEN, MICHAELA MATTHEUS, ANNETT KELLER, ODD ERIK JOHANSEN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):926-P
https://doi.org/10.2337/db20-926-P
Published: 01 June 2020
View article titled, 926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial
Meeting Abstracts

952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial

BERNARD ZINMAN, JULIO ROSENSTOCK, ODD ERIK JOHANSEN, MIKKEL HOEIBERG, EGON PFARR, MICHAELA MATTHEUS, THOMAS MEINICKE, JYOTHIS T. GEORGE, MARK ESPELAND, DARREN K. MCGUIRE, NIKOLAUS MARX, STEVEN E. KAHN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):952-P
https://doi.org/10.2337/db20-952-P
Published: 01 June 2020
View article titled, 952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial
Meeting Abstracts

144-LB: Medicaid Expansion and Utilization of Antihyperglycemic Therapies

ANDREW SUMARSONO, LEO BUCKLEY, SARA R. MACHADO, RISHI K. WADHERA, HAIDER WARRAICH, RISHI J. DESAI, BRENDAN M. EVERETT, DARREN K. MCGUIRE, GREGG C. FONAROW, JAVED BUTLER, AMBARISH PANDEY, MUTHIAH VADUGANATHAN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):144-LB
https://doi.org/10.2337/db20-144-LB
Published: 01 June 2020
View article titled, 144-LB: Medicaid Expansion and Utilization of Antihyperglycemic Therapies
Meeting Abstracts

1-OR: Analyses of First Plus Recurrent Cardiovascular (CV) and Hospitalization Events in the CAROLINA Trial

NIKOLAUS MARX, DARREN K. MCGUIRE, ODD ERIK JOHANSEN, JULIO ROSENSTOCK, EGON PFARR, MICHAELA MATTHEUS, JYOTHIS T. GEORGE, MARK ESPELAND, BERNARD ZINMAN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1-OR
https://doi.org/10.2337/db20-1-OR
Published: 01 June 2020
View article titled, 1-OR: Analyses of First Plus Recurrent Cardiovascular (CV) and Hospitalization Events in the CAROLINA Trial
Meeting Abstracts

1224-P: Validation of a New Diabetes Staging System (DSS) for Type 2 Diabetes (T2D) Using Data from Three Cardiovascular Outcomes Trials (CVOTs)

MOAHAD DAR, CHRISTOPH WANNER, NIKOLAUS MARX, ODD ERIK JOHANSEN, ANNE PERNILLE OFSTAD, MICHAELA MATTHEUS, STEFAN KASPERS, JYOTHIS T. GEORGE, JULIO ROSENSTOCK, DARREN K. MCGUIRE, SAMI A. BEG
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1224-P
https://doi.org/10.2337/db20-1224-P
Published: 01 June 2020
View article titled, 1224-P: Validation of a New Diabetes Staging System (DSS) for Type 2 Diabetes (T2D) Using Data from Three Cardiovascular Outcomes Trials (CVOTs)
Meeting Abstracts

1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58

AVIVIT CAHN, STEPHEN D. WIVIOTT, OFRI MOSENZON, SABINA MURPHY, ERICA L. GOODRICH, ILAN YANUV, ALIZA ROZENBERG, JOHN WILDING, LAWRENCE A. LEITER, DEEPAK L. BHATT, DARREN K. MCGUIRE, LEON LITWAK, ADRIAAN KOOY, INGRID A. GAUSE-NILSSON, MARTIN FREDRIKSSON, ANNA MARIA LANGKILDE, MARC S. SABATINE, ITAMAR RAZ
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1101-P
https://doi.org/10.2337/db20-1101-P
Published: 01 June 2020
View article titled, 1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58